DOCSLIB.ORG

A Ten-Year Retrospective Study of Cervical Conization Followed by Hysterectomy for Various Grades of Cervical Intraepithelial Neoplasia

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A Ten-Year Retrospective Study of Cervical Conization Followed by Hysterectomy for Various Grades of Cervical Intraepithelial Neoplasia A ten-year retrospective study of cervical conization followed by hysterectomy for various grades of cervical intraepithelial neoplasia CLAYTON T. SHAW, D 0 Omaha, Nebraska HEINZ 0. OSTERHOLZER, m D Philadelphia, Pennsylvania DAVID M. EVANS, m D Wiesbaden, West Germany They are: (1) visualization of the entire lesion; (2) A ten-year retrospective study of expertise in colposcopy; (3) exclusion of invasive seventy-seven patients from January carcinoma by punch biopsy; (4) adequate cytologic 1971 to December 1980, at the Tripler and colposcopic follow-up; and (5) endocervical Army Medical Center, who curettage. underwent cold knife conization for Conization as a modality, however, is considered cervical intraepithelial neoplasia a definitive therapy for the removal of dysplastic (CIN) followed by hysterectomy, was tissue and is required if the colposcopic examina- performed to determine the tion is inadequate or the endocervical curettage is predictive value of cone clearance positive for CIN. Kolstad stated that conization is regarding residual CIN. Forty-four of the method of choice for carcinoma in situ. He the seventy-seven patients had found a 97 percent cure rate with 1 percent pro- clear cone margins but seven of these gressing to invasive carcinoma and 2 percent to re- forty-four had residual CIN at the current carcinoma in situ. Caglar 9 also studied the time of hysterectomy. This accuracy of the cervical cone. He performed coniza- represented a 15.9 percent tion in thirty-three patients and immediately fol- recurrence rate. Thirty-three patients lowed that procedure with a vaginal hysterectomy. had margins involved at the time of He found that in three patients (9 percent) of the conization, but only fourteen of these uteri specimens had the same diagnosis as the con- (42.4 percent) demonstrated residual ization. Jones" reported recurrence rates of 3.8 to CIN on hysterectomy specimen. 9.4 percent from a number of studies between 1970 Twenty-eight of the seventy-seven and 1976. An earlier report from Tripler Army were noted to have at least one Medical Center also demonstrated a similar cure concurrent gynecologic condition. rate." Ostergard," however, recently found that The efficacy of cold knife conization 16 percent of patients with clear cone margins and as a "cure" for CIN as generally 34 percent with involved margins had residual stated in the literature is not CIN. He concluded that a prediction cannot be supported by this paper. made as to recurrence based on cleared margin and that a failure rate is closer to 16 percent in skilled hands. The question then arises—Is coniza- tion as a definitive therapy really as good as ori- ginally perceived? The purpose of this study was to determine the Cervical intraepithelial neoplasia (CIN) is of ma- predictive value of cone clearance regarding resid- jor concern to the gynecologist because of its pre- ual CIN. It was the authors desire to determine cancerous nature. Since this disease is a contin- the following: (1) the cone pathology; (2) the num- uum and may well lead to invasive cancer, it is the ber of cone slides; (3) the cone margins; (4) hyster- obligation of the gynecologist to diagnose, treat, ectomy pathology for residual CIN; (5) the number and closely follow patients with CIN. Whether a of hysterectomy slides; and (6) concurrent gyneco- gynecologist utilizes cryosurgery, carbon dioxide logic pathology at the time of hysterectomy. laser therapy, or electrocoagulation diathermy, he can expect a cure rate of from 88 to 95 percent," Materials and methods provided that he follows the pretreatment evalua- A retrospective study of seventy-seven patients tion standards set down by Jordan and Chanen.7 who underwent conization for CIN from January Ten-year retrospective study of cervical conization followed by hysterectomy for various grades of cervical intraepithelial neoplasia 994/65 TABLE 1. RELATIONSHIP OF AGE, CLEAR CONE MARGINS, INVOLVED terval of 12 weeks between conization and hyster- ENDOCERVICAL CONE MARGINS, INVOLVED ECTOCERVICAL CONE ectomy. MARGINS, AND SEVERITY OF CIN. The charts of the seventy-seven patients who Clear Involved Involved had a conization as well as hysterectomy were re- cone endocervical ectocervical trieved. These charts were examined for the afore- margin margin margin mentioned criteria to determine if conization for Age CIN I II III CIN I II III CIN I II III these patients supported the general literature or 25-29 7 7 1 Ostergards study. There were an average of 15 mi- 30-34 1 1 18 2 3 3 croscopic sections for conization specimens and an 35-39 2 7 1 1 5 2 average of 12 microscopic sections for the hysterec- 40-44 3 1 2 1 tomy specimens. All of the cone slides in the study 45+2– – — 1 1 5 _ _ Totals 6 2 36 2 4 21 1 5 were examined for margin clearance by the au- thors. The cone specimen was then matched with TABLE 2. RELATIONSHIP OF AGE, CLEAR CONE MARGIN WITH NO RE- SIDUAL CIN, AND CLEAR CONE MARGIN WITH RESIDUAL CIN AT THE its corresponding hysterectomy specimen to deter- TIME OF HYSTERECTOMY. mine the efficacy of conization in the treatment of Clear cone margin CIN. Residual CIN Clear cone margin ,------A----, Results Age No residual CIN CIN I II III Table 1 shows that forty-four of the seventy-seven 25-29 5 2 patients who had conization demonstrated clear 30-34 16 3 1 35-39 8 1 cone margins; thirty-six of these forty-four (81.8 40-44 6 percent) were diagnosed as having CIN III. There 45+ 2 — were twenty-seven patients with an involved en- 37 7 Totals docervical margin, twenty-one of whom (77.7 per- TABLE 3. RELATIONSHIP OF AGE, INVOLVED CONE MARGINS WITH cent) had CIN III. Six patients had involved ecto- NO RESIDUAL CIN, AND INVOLVED CONE MARGINS WITH RESIDUAL cervical margins, five of whom (83.3 percent) had CIN AT THE TIME OF HYSTERECTOMY. CIN III. The total number of patients with in- Involved cone margin volved cervical cone margins was thirty-three Residual CIN Involved cone margin ,----"------, (42.8 percent) and of these thirty-three, CIN III Age No residual CIN CIN I II III was found in twenty-six patients (78.7 percent). 25-29 6 1 1 • Table 2 shows that in this population, seven of 30-34 6 2 the forty-four patients (15.9 percent) who had clear 35-39 3 1 5 cone margins had residual dysplasia at the time of 40-44 1 45+ 3 1 3 hysterectomy. When these seven were reviewed, it Totals 19 14 was determined that six of the seven had CIN III and one had CIN II diagnosed at the time of coniza- TABLE 4. COMPARISON OF AGE, HYSTERECTOMY SPECIMENS WITH tion. This residual rate is consistent with Oster- NO RESIDUAL CIN AND WITH RESIDUAL CIN. gards study which demonstrated a 16 percent re- Specimens with residual CIN sidual rate. Specimens without Table 3 shows that fourteen of the thirty-three Age residual CIN CIN I II III patients (42.4 percent) who had involved cone mar- 25-29 11 1 2 1 gins continued to have residual CIN at the time of 30-34 22 3 3 hysterectomy. When these fourteen were re- 35-39 11 1 6 40-44 7 viewed, it was determined that ten of the fourteen 45+ 5 1 3 had CIN III on both the cone and hysterectomy Totals 56 21 specimen, one had CIN III on the cone and CIN II at hysterectomy, one had CIN H on the cone and CIN III at hysterectomy, and one had CIN III at 1971 to December 1980 and followed with hyster- cone and CIN I at hysterectomy. This residual rate ectomy at, the Tripler Army Medical Center was for involved cone margins (42.4 percent) is higher performed. These seventy-seven represented the than Ostergards study which demonstrated a 34 population of patients who had a cold-knife coniza- percent residual rate. tion and were followed by hysterectomy, as deter- Table 4 shows that there were 56 hysterectomy mined by computer files at the center. specimens that had no residual CIN. These 56 in- Three patients had their hysterectomy immedi- cluded 37 specimens with prior clear margins as ately following conization and two had a hysterec- well as 19 specimens that were involved at the tomy nearly two years following their conization. time of conization. There were 21 hysterectomy The other seventy-two patients had an average in- specimens which contained residual CIN. These 21 295/66 Dec. 1983/Joumal of AOA/vol. 83/no. 4 included 14 specimens that had involved margins TABLE 5. CONCURRENT GYNECOLOGIC CONDITIONS FOUND IN 77 PA- at the time of conization which remained involved TIENTS WHO UNDERWENT HYSTERECTOMY FOR VARIOUS GRADES as well as 7 specimens that were clear at the time OF CIN. of conization but demonstrated CIN at the time of Number Condition hysterectomy. The total residual CIN rate was 10 Leiomyomata 27.3 percent (twenty-one of seventy-seven pa- 5 Adenomyosis and leiomyomata tients). There were 13 hysterectomy specimens 3 Adenomyosis 2 Endometriosis that demonstrated CIN III. This was 61.9 percent 1 Hydrosalpinx of those specimens with residual dysplasia. 1 Adenomyosis and acute salpingitis Table 5 shows that there were twenty-eight pa- 1 Adenomatous hyperplasia 1 Chronic pelvic inflammatory disease tients out of the seventy-seven in the study (36.4 1 Adenomatous change with atypia and percent) who demonstrated at least one concurrent leiomyomata gynecologic condition. Pure leiomyomata uteri or 1 Benign cystic teratoma 1 Endocervical polyp concurrent adenomyosis accounted for fifteen pa- 1 Stress urinary incontinence tients.
Load more

Recommended publications
  • Updates in Uterine and Vulvar Cancer
    Management of GYN Malignancies Junzo Chino MD Duke Cancer Center ASTRO Refresher 2015 Disclosures • None Learning Objectives • Review the diagnosis, workup, and management of: – Cervical Cancers – Uterine Cancers – Vulvar Cancers Cervical Cancer Cervical Cancer • 3rd most common malignancy in the World • 2nd most common malignancy in women • The Leading cause of cancer deaths in women for the developing world • In the US however… – 12th most common malignancy in women – Underserved populations disproportionately affected > 6 million lives saved by the Pap Test “Diagnosis of Uterine Cancer by the Vaginal Smear” Published Pap Test • Start screening within 3 years of onset of sexual activity, or at age 21 • Annual testing till age 30 • If no history of abnormal paps, risk factors, reduce screening to Q2-3 years. • Stop at 65-70 years • 5-7% of all pap tests are abnormal – Majority are ASCUS Pap-test Interpretation • ASCUS or LSIL –> reflex HPV -> If HPV + then Colposcopy, If – Repeat in 1 year • HSIL -> Colposcopy • Cannot diagnose cancer on Pap test alone CIN • CIN 1 – low grade dysplasia confined to the basal 1/3 of epithelium – HPV negative: repeat cytology at 12 months – HPV positive: Colposcopy • CIN 2-3 – 2/3 or greater of the epithelial thickness – Cold Knife Cone or LEEP • CIS – full thickness involvement. – Cold Knife Cone or LEEP Epidemiology • 12,900 women expected to be diagnosed in 2015 – 4,100 deaths due to disease • Median Age at diagnosis 48 years Cancer Statistics, ACS 2015 Risk Factors: Cervical Cancer • Early onset sexual activity • Multiple sexual partners • Hx of STDs • Multiple pregnancy • Immune suppression (s/p transplant, HIV) • Tobacco HPV • The human papilloma virus is a double stranded DNA virus • The most common oncogenic strains are 16, 18, 31, 33 and 45.
    [Show full text]
  • Treating Cervical Cancer If You've Been Diagnosed with Cervical Cancer, Your Cancer Care Team Will Talk with You About Treatment Options
    cancer.org | 1.800.227.2345 Treating Cervical Cancer If you've been diagnosed with cervical cancer, your cancer care team will talk with you about treatment options. In choosing your treatment plan, you and your cancer care team will also take into account your age, your overall health, and your personal preferences. How is cervical cancer treated? Common types of treatments for cervical cancer include: ● Surgery for Cervical Cancer ● Radiation Therapy for Cervical Cancer ● Chemotherapy for Cervical Cancer ● Targeted Therapy for Cervical Cancer ● Immunotherapy for Cervical Cancer Common treatment approaches Depending on the type and stage of your cancer, you may need more than one type of treatment. For the earliest stages of cervical cancer, either surgery or radiation combined with chemo may be used. For later stages, radiation combined with chemo is usually the main treatment. Chemo (by itself) is often used to treat advanced cervical cancer. ● Treatment Options for Cervical Cancer, by Stage Who treats cervical cancer? Doctors on your cancer treatment team may include: 1 ____________________________________________________________________________________American Cancer Society cancer.org | 1.800.227.2345 ● A gynecologist: a doctor who treats diseases of the female reproductive system ● A gynecologic oncologist: a doctor who specializes in cancers of the female reproductive system who can perform surgery and prescribe chemotherapy and other medicines ● A radiation oncologist: a doctor who uses radiation to treat cancer ● A medical oncologist: a doctor who uses chemotherapy and other medicines to treat cancer Many other specialists may be involved in your care as well, including nurse practitioners, nurses, psychologists, social workers, rehabilitation specialists, and other health professionals.
    [Show full text]
  • WHO Guidelines for Treatment of Cervical Intraepithelial Neoplasia 2–3 and Adenocarcinoma in Situ
    WHO guidelines WHO guidelines for treatment of cervical intraepithelial neoplasia 2–3 and adenocarcinoma in situ Cryotherapy Large loop excision of the transformation zone Cold knife conization WHO guidelines WHO guidelines for treatment of cervical intraepithelial neoplasia 2–3 and adenocarcinoma in situ: cryotherapy, large loop excision of the transformation zone, and cold knife conization Catalogage à la source : Bibliothèque de l’OMS WHO guidelines for treatment of cervical intraepithelial neoplasia 2–3 and adenocarcinoma in situ: cryotherapy, large loop excision of the transformation zone, and cold knife conization. 1.Cervical Intraepithelial Neoplasia – diagnosis. 2.Cervical Intraepithelial Neoplasia – therapy. 3.Cervical Intraepithelial Neoplasia – surgery. 4.Adenocarcinoma – diagnosis. 5.Adenocarcinoma – therapy. 6.Cryotherapy – utilization. 7.Conization – methods. 8.Uterine Cervical Neoplasms – prevention and control. 9.Guideline. I.World Health Organization. ISBN 978 92 4 150677 9 (Classification NLM : WP 480) © World Health Organization 2014 All rights reserved. Publications of the World Health Organization are available on the WHO website (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for non-commercial distribution – should be addressed to WHO Press through the WHO website (www.who.int/about/licensing/copyright_form/en/index.html). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.
    [Show full text]
  • Cervical Cancer
    Cervical Cancer Ritu Salani, M.D., M.B.A. Assistant Professor, Dept. of Obstetrics & Gynecology Division of Gynecologic Oncology The Ohio State University Estimated gynecologic cancer cases United States 2010 Jemal, A. et al. CA Cancer J Clin 2010; 60:277-300 1 Estimated gynecologic cancer deaths United States 2010 Jemal, A. et al. CA Cancer J Clin 2010; 60:277-300 Decreasing Trends of Cervical Cancer Incidence in the U.S. • With the advent of the Pap smear, the incidence of cervical cancer has dramatically declined. • The curve has been stable for the past decade because we are not reaching the unscreened population. Reprinted by permission of the American Cancer Society, Inc. 2 Cancer incidence worldwide GLOBOCAN 2008 Cervical Cancer New cases Deaths United States 12,200 4,210 Developing nations 530,000 275,000 • 85% of cases occur in developing nations ¹Jemal, CA Cancer J Clin 2010 GLOBOCAN 2008 3 Cervical Cancer • Histology – Squamous cell carcinoma (80%) – Adenocarcinoma (15%) – Adenosquamous carcinoma (3 to 5%) – Neuroendocrine or small cell carcinoma (rare) Human Papillomavirus (HPV) • Etiologic agent of cervical cancer • HPV DNA sequences detected is more than 99% of invasive cervical carcinomas • High risk types: 16, 18, 45, and 56 • Intermediate types: 31, 33, 35, 39, 51, 52, 55, 58, 59, 66, 68 HPV 16 accounts for ~80% of cases HPV 18 accounts for 25% of cases Walboomers JM, Jacobs MV, Manos MM, et al. J Pathol 1999;189(1):12-9. 4 Viral persistence and Precancerous progression Normal lesion cervix Regression/ clearance Invasive cancer Risk factors • Early age of sexual activity • Cigggarette smoking • Infection by other microbial agents • Immunosuppression – Transplant medications – HIV infection • Oral contraceptive use • Dietary factors – Deficiencies in vitamin A and beta carotene 5 Multi-Stage Cervical Carcinogenesis Rosenthal AN, Ryan A, Al-Jehani RM, et al.
    [Show full text]
  • Colposcopy of the Uterine Cervix
    THE CERVIX: Colposcopy of the Uterine Cervix • I. Introduction • V. Invasive Cancer of the Cervix • II. Anatomy of the Uterine Cervix • VI. Colposcopy • III. Histology of the Normal Cervix • VII: Cervical Cancer Screening and Colposcopy During Pregnancy • IV. Premalignant Lesions of the Cervix The material that follows was developed by the 2002-04 ASCCP Section on the Cervix for use by physicians and healthcare providers. Special thanks to Section members: Edward J. Mayeaux, Jr, MD, Co-Chair Claudia Werner, MD, Co-Chair Raheela Ashfaq, MD Deborah Bartholomew, MD Lisa Flowers, MD Francisco Garcia, MD, MPH Luis Padilla, MD Diane Solomon, MD Dennis O'Connor, MD Please use this material freely. This material is an educational resource and as such does not define a standard of care, nor is intended to dictate an exclusive course of treatment or procedure to be followed. It presents methods and techniques of clinical practice that are acceptable and used by recognized authorities, for consideration by licensed physicians and healthcare providers to incorporate into their practice. Variations of practice, taking into account the needs of the individual patient, resources, and limitation unique to the institution or type of practice, may be appropriate. I. AN INTRODUCTION TO THE NORMAL CERVIX, NEOPLASIA, AND COLPOSCOPY The uterine cervix presents a unique opportunity to clinicians in that it is physically and visually accessible for evaluation. It demonstrates a well-described spectrum of histological and colposcopic findings from health to premalignancy to invasive cancer. Since nearly all cervical neoplasia occurs in the presence of human papillomavirus infection, the cervix provides the best-defined model of virus-mediated carcinogenesis in humans to date.
    [Show full text]
  • UNMH Obstetrics and Gynecology Clinical Privileges Name
    UNMH Obstetrics and Gynecology Clinical Privileges Name:____________________________ Effective Dates: From __________ To ___________ All new applicants must meet the following requirements as approved by the UNMH Board of Trustees, effective April 28, 2017: Initial Privileges (initial appointment) Renewal of Privileges (reappointment) Expansion of Privileges (modification) INSTRUCTIONS: Applicant: Check off the “requested” box for each privilege requested. Applicants have the burden of producing information deemed adequate by the Hospital for a proper evaluation of current competence, current clinical activity, and other qualifications and for resolving any doubts related to qualifications for requested privileges. Department Chair: Check the appropriate box for recommendation on the last page of this form. If recommended with conditions or not recommended, provide condition or explanation. OTHER REQUIREMENTS: 1. Note that privileges granted may only be exercised at UNM Hospitals and clinics that have the appropriate equipment, license, beds, staff, and other support required to provide the services defined in this document. Site-specific services may be defined in hospital or department policy. 2. This document defines qualifications to exercise clinical privileges. The applicant must also adhere to any additional organizational, regulatory, or accreditation requirements that the organization is obligated to meet. ---------------------------------------------------------------------------------------------------------------------------------------
    [Show full text]
  • Pretest Obstetrics and Gynecology
    Obstetrics and Gynecology PreTestTM Self-Assessment and Review Notice Medicine is an ever-changing science. As new research and clinical experience broaden our knowledge, changes in treatment and drug therapy are required. The authors and the publisher of this work have checked with sources believed to be reliable in their efforts to provide information that is complete and generally in accord with the standards accepted at the time of publication. However, in view of the possibility of human error or changes in medical sciences, neither the authors nor the publisher nor any other party who has been involved in the preparation or publication of this work warrants that the information contained herein is in every respect accurate or complete, and they disclaim all responsibility for any errors or omissions or for the results obtained from use of the information contained in this work. Readers are encouraged to confirm the information contained herein with other sources. For example and in particular, readers are advised to check the prod- uct information sheet included in the package of each drug they plan to administer to be certain that the information contained in this work is accurate and that changes have not been made in the recommended dose or in the contraindications for administration. This recommendation is of particular importance in connection with new or infrequently used drugs. Obstetrics and Gynecology PreTestTM Self-Assessment and Review Twelfth Edition Karen M. Schneider, MD Associate Professor Department of Obstetrics, Gynecology, and Reproductive Sciences University of Texas Houston Medical School Houston, Texas Stephen K. Patrick, MD Residency Program Director Obstetrics and Gynecology The Methodist Health System Dallas Dallas, Texas New York Chicago San Francisco Lisbon London Madrid Mexico City Milan New Delhi San Juan Seoul Singapore Sydney Toronto Copyright © 2009 by The McGraw-Hill Companies, Inc.
    [Show full text]
  • Cervical Health Policies Program Description the Breast, Cervical and Colon Health Program (BCCHP) Screens Qualifying Clients for Cervical Cancer
    DOH 342-035 July 2018 Cervical Health Policies Program Description The Breast, Cervical and Colon Health Program (BCCHP) screens qualifying clients for cervical cancer. The program is funded through a grant from the Centers for Disease Control and Prevention (CDC). It is administered by the Washington State Department of Health which contracts with Prime Contractors throughout the state to implement the program regionally. The Prime Contractors subcontract with health care providers and organizations to provide direct services to individuals in their communities. BCCHP eligibility and screening policies reflect CDC guidelines. Eligibility & Coverage Gender Definitions for terms used in BCCHP policies • Cisgender - a person whose gender identification and birth sex are the same. • Transgender man - a person who identifies as male with a female-assigned birth sex. • Transgender woman - a person who identifies as female with a male-assigned birth sex. • Genderqueer - A person whose gender identity differs from the gender assigned at birth, but may less clearly defined than a transgender person. • Gender Non-binary - a person who neither identifies as a male nor female with either a female assigned birth sex or a male-assigned birth sex. • Agender – A person who does not identify with any gender. Eligible – Cisgender women and transgender men who meet the following criteria: Must meet all of the following: • Age 40-64 (through the end of the month of client’s 65th birthday). • Age 65+ if the client is not eligible for Medicare or ineligible for Medicare Part B at the time of enrollment. • Age 21-39 if the client is not covered by Family Planning or Title X Clinic funding.
    [Show full text]
  • Colposcopy, Treatment of Cervical Intraepithelial Neoplasia, and Endometrial Assessment BARBARA S
    Gynecologic Procedures: Colposcopy, Treatment of Cervical Intraepithelial Neoplasia, and Endometrial Assessment BARBARA S. APGAR, MD; AMANDA J. KAUFMAN, MD; CATHERINE BETTCHER, MD; and EBONY PARKER-FEATHERSTONE, MD, University of Michigan Medical Center, Ann Arbor, Michigan Women who have abnormal Papanicolaou test results may undergo colposcopy to determine the biopsy site for his- tologic evaluation. Traditional grading systems do not accurately assess lesion severity because colposcopic impres- sion alone is unreliable for diagnosis. The likelihood of finding cervical intraepithelial neoplasia grade 2 or higher increases when two or more cervical biopsies are performed. Excisional and ablative methods have similar treatment outcomes for the eradication of cervical intraepithelial neoplasia. However, diagnostic excisional methods, including loop electrosurgical excision procedure and cold knife conization, are associated with an increased risk of adverse obstetric outcomes, such as preterm labor and low birth weight. Methods of endometrial assessment have a high sen- sitivity for detecting endometrial carcinoma and benign causes of uterine bleeding without unnecessary procedures. Endometrial biopsy can reliably detect carcinoma involving a large portion of the endometrium, but is suboptimal for diagnosing focal lesions. A 3- to 4-mm cutoff for endometrial thickness on transvaginal ultrasonography yields the highest sensitivity to exclude endometrial carcinoma in postmenopausal women. Saline infusion sonohysteros- copy can differentiate
    [Show full text]
  • Cervical Health Policies Program Description the Breast, Cervical and Colon Health Program (BCCHP) Screens Qualifying Clients for Cervical Cancer
    DOH 342-035 July 2018 Cervical Health Policies Program Description The Breast, Cervical and Colon Health Program (BCCHP) screens qualifying clients for cervical cancer. The program is funded through a grant from the Centers for Disease Control and Prevention (CDC). It is administered by the Washington State Department of Health which contracts with Prime Contractors throughout the state to implement the program regionally. The Prime Contractors subcontract with health care providers and organizations to provide direct services to individuals in their communities. BCCHP eligibility and screening policies reflect CDC guidelines. Eligibility & Coverage Gender Definitions for terms used in BCCHP policies • Cisgender - a person whose gender identification and birth sex are the same. • Transgender man - a person who identifies as male with a female-assigned birth sex. • Transgender woman - a person who identifies as female with a male-assigned birth sex. • Genderqueer - A person whose gender identity differs from the gender assigned at birth but may be less clearly defined than a transgender person. • Gender Non-binary - a person who neither identifies as a male nor female with either a female assigned birth sex or a male-assigned birth sex. • Agender – A person who does not identify with any gender. Eligible – Cisgender women and transgender men who meet the following criteria: Must meet all of the following: • Age 40-64 (through the end of the month of client’s 65th birthday). • Age 65+ if the client is not eligible for Medicare or ineligible for Medicare Part B at the time of enrollment. • Age 21-39 if the client is not covered by Family Planning or Title X Clinic funding • Uninsured or underinsured.
    [Show full text]
  • The Effects of Different Instruments and Suture Methods of Conization for Cervical Lesions
    www.nature.com/scientificreports OPEN The efects of diferent instruments and suture methods of conization for cervical lesions Xiaoyu Wang1, Lei Li 1*, Yalan Bi2, Huanwen Wu2, Ming Wu 1 & Jinghe Lang1 This study is to compare the surgical outcomes of patients undergoing cold knife conization (CKC) versus electrosurgical conization (ESC). Among 10,086 patients in a single center admitted between January 2000 and January 2019, CKS or ESC was used for grade 3 cervical intraepithelial neoplasia (CIN3) or more severe lesions. Modifed Sturmdorf or Figure-of-eight sutures were applied after conization. A regression model was used to determine the risk factors for margin involvement and short-term post-operative complications. In total, 7275 (72.1%) and 2811 (27.9%) patients underwent CKC and ESC, respectively. Women who underwent ESC were older and had a higher risk of margin involvement and endocervical glandular involvement than those who underwent CKC in univariate analysis. However, in the multivariate analysis, age (odds ratio [OR] 1.032, 95% confdence interval [95% CI] 1.025–1.038) and glandular involvement (OR 2.196, 95% CI 1.915–2.517) were the independent risk factors associated with margin involvement, but the incision methods used caused no signifcant diference. Modifed Sturmdorf sutures and Figure-of-eight sutures were applied in 3520 (34.9%) and 6566 (65.1%) patients, respectively. The modifed Sturmdorf sutures was the only risk factor associated with wound hemorrhage (OR 1.852, 95% CI 1.111–3.085) after adjusted with other epidemiological and surgical factors. Various incision or suture methods had similar risk of cervical stenosis.
    [Show full text]
  • Obstetrics and Gynecology: Gynecologic Oncology Rotation Objectives, Core of Discipline
    Obstetrics and Gynecology: Gynecologic Oncology Rotation Page 1 of 8 Objectives , Core of Discipline CanMEDS Framework: Medical Expert, Communicator, Collaborator, Leader, Health Advocate, Rotation Contacts Scholar, and Professional. Rotation Contact: Gynecologic Oncology Learning Objectives Dr. Jeanelle Sabourin Reading material: The general objectives of the gynecologic oncology rotation are to provide the resident with Prior to this rotation, the resident comprehensive exposures and knowledge of gynecologic oncology with an emphasis on should read the Resident orientation screening, prevention, diagnosis, and treatment of premalignant and malignant conditions of package. the female reproductive organs. Upon completion of training, the resident is expected to be a competent specialist capable of assuming an independent consultant’s role in obstetrics and Rotation duration: gynecology. They must have acquired the necessary knowledge, skills, and attitudes for 3 Blocks appropriate and competent management of a wide range of gynecologic oncology conditions. Vacation and time off: General Objectives: Maximum total vacation and conference time away: 2 weeks. Refer to Para Develop an understanding of the following; embryology and normal female development, guidelines and the vacation policy. the unique biochemistry, physiology, anatomy, and gross and the microscopic pathology Review of rotation objectives: Rotation of the genitourinary tract. objectives should be reviewed with the Develop a working understanding of the normal function and the pathological processes resident soon after their rotation and diseases that affect the female external genitalia and the pelvic viscera, including the begins. vagina, cervix, uterus, fallopian tubes, ovaries, the lower urinary tract, and the bowel. Assessment: The ability to develop a trusting and productive partnership with patients to manage and There are no formal/scored support patients with gynecological cancer.
    [Show full text]